Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Daiichi Sankyo’s Enhertu, Novartis’ Beovu, Novo’s Ozempic OK’ed for Listing on May 20
Japan’s all-important reimbursement policy panel on May 13 approved the listing of 18 drugs on May 20 including Daiichi Sankyo’s cancer drug Enhertu (trastuzumab deruxtecan) and Novartis’ wet age-related macular degeneration (AMD) treatment Beovu (brolucizumab). The Central Social Insurance Medical…
To read the full story
Related Article
- Novartis Launches AMD Drug Beovu in Japan
May 26, 2020
- Daiichi Sankyo’s Enhertu Hits Japan Market for Breast Cancer
May 26, 2020
- As Beovu Debut Nears, Novartis Set to Push Longer Dosing Interval, Pivotal Data in Battle against Eylea
May 22, 2020
- Nippon Shinyaku’s DMD Drug Now Available in Japan; AZ’s Lokelma, Ono’s Velexbru Too
May 21, 2020
- Japan OKs Enhertu, 3 Sakigake Drugs, Beovu, Latuda, and More
March 26, 2020
- Japan OKs Novo’s Single-Dose Pen Devices for List-Pending Ozempic
March 16, 2020
REGULATORY
- Japan’s New HIV Cases Hit 20-Year Low in 2025
March 30, 2026
- MHLW Launches Genomic Medicine Body GeMJ
March 30, 2026
- TNF Inhibitors, Cancer Drugs Flagged in PMDA Risk Review
March 30, 2026
- Japan Ranks 9th Among 10 in AI Analysis of EFPIA Pharma Strategy Report
March 27, 2026
- MHLW Says Trial Recruitment Info Not Deemed Advertising Under PMD Act
March 27, 2026
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…